After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.7 on the Global strategy and plan of action on public health, innovation and intellectual property either on Wednesday, 24 January 2018 or Thursday, 25 January 2018.… Continue Reading
On Wednesday, 24 January 2018, the World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.6 on Addressing the global shortage of, and access to, medicines and vaccines. Non-state actors in official relations with the WHO are… Continue Reading
From November 21 to 23, the Government of India and the World Health Organization are hosting the “1st World Conference on Access to Medical Products and International Laws for Trade and Health, in the Context of the 2030 Agenda for… Continue Reading
On Wednesday, 24 May 2017, Knowledge Ecology International (KEI), Oxfam and Stichting Health Action International (HAI) are convening a side event on addressing access barriers and affordability challenges for cancer medicines. This panel will take place in Salle IX of the United Nations Palais des Nations from 18:00 to 19:30.
Date: Wednesday, 24 May 2017
Time: 18:00 to 19:30
Location: Salle IX, United Nations Palais des NationsPanelists:
Experts, NGOs ask WHA delegates to support feasibility study of funding cancer research without high prices
On May 3, 2017, 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asked delegates to the World Health Assembly (WHA) to support a feasibility study on the progressive delinkage of the costs of research and development from the price of cancer medicines. The groups and experts sent a letter to the delegates.
EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to Medicines
On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization’s Executive Board requesting the “explicit inclusion” of the United Nations Secretary-General’s High-Level Panel Report in the “provisional agenda of the EB140 as a separate agenda item under item 8.”
In making the case for the inclusion of the UN HLP in the WHO’s Executive Board deliberations, India articulate the following:
9 November 2016 – WTO TRIPS Council – WHO’s intervention on the Report of the UN High-Level Panel on Access to Medicines
On Wednesday, 9 November 2016, the World Health Organization (WHO) delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
COUNCIL FOR TRIPS
8-9 NOVEMBER 2016
WHO STATEMENT
13. THE UNITED NATIONS SECRETARY-GENERAL’S HIGH LEVEL PANEL REPORT ON ACCESS TO MEDICINES
Thank you very much for giving WHO the opportunity to share our feedback on the Report of the High-Level Panel on Access to Medicines.
KEI December 2, 2016 meeting on the delinkage of R&D costs from drug prices
KEI is holding a December 2, 2016 meeting on the delinkage of R&D costs from drug prices. The venue will be US Senate Hearing Room SD-106, Dirksen Office Building. The meeting will take place from 9:00am to 2:00pm. A copy… Continue Reading
Summary of Report of United Nations Secretary-General’s High-Level Panel on Access to Medicines
On September 14, 2016, the United Nations Secretary-General’s High-Level Panel on Access to Medicines released its report, in which they had a mandate to “review and assess proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies.”[1]